Asthma Therapeutics in Major Developed Markets to 2020 – Personalized … – PR Newswire (press release)

Asthma Therapeutics in Major Developed Markets to 2020 – Personalized
PR Newswire (press release)
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4

and more »

View full post on asthma – Google News

Asthma Therapeutics Market Set to be Dominated by Personalized Treatment … – Medgadget.com (blog)

Asthma Therapeutics Market Set to be Dominated by Personalized Treatment
Medgadget.com (blog)
Asthma is an inevitable consequence of the Industrial age and is consequently on the rise in the modern world. Growing pollution from the industrial sector and the ever-growing number of vehicles plying the roads is contributing to a widening
Global asthma therapeutics market to 2020 : personalized treatment for Severe WhaTech

all 2 news articles »

View full post on asthma – Google News

Asthma Therapeutics Market to 2020 – Personalized Treatment for Severe … – Medgadget.com (blog)


Medgadget.com (blog)

Asthma Therapeutics Market to 2020 – Personalized Treatment for Severe
Medgadget.com (blog)
The global prevalence of asthma, a chronic inflammatory disease of the airways, has risen considerably in recent decades and is expected to reach 400 million people by 2025. This high prevalence is a substantial contributor to healthcare costs and a

View full post on asthma – Google News

Medicaid Health Plan Offers Personalized Medication Adherence Platform for … – HIT Consultant


HIT Consultant

Medicaid Health Plan Offers Personalized Medication Adherence Platform for
HIT Consultant
AmeriHealth D.C., the largest Medicaid managed care organization in the District announced it will offer its members a personalized digital mobile platform aimed at improving medication adherence for asthma patients. The platform called HealthNHandSM …

View full post on asthma – Google News

Asthma’s treatment pipeline very strong as more personalized medicines emerge – The Pharma Letter

Asthma's treatment pipeline very strong as more personalized medicines emerge
The Pharma Letter
According to research and consulting firm GlobalData's latest report, the most significant challenge in asthma therapeutics is posed by patients with severe forms of the disease, who remain uncontrolled and have frequent exacerbations, even with the …

View full post on asthma – Google News

A Computational Physiology Approach to Personalized Treatment Models: The Beneficial Effects of Slow Breathing on the Human Cardiovascular System.

A Computational Physiology Approach to Personalized Treatment Models: The Beneficial Effects of Slow Breathing on the Human Cardiovascular System.

Am J Physiol Heart Circ Physiol. 2014 Jul 25;

Authors: Fonoberova M, Mezic I, Buckman JF, Fonoberov VA, Mezic A, Vaschillo E, Mun EY, Vaschillo B, Bates ME

Abstract
Heart rate variability biofeedback intervention involves slow breathing at a rate of ~6 breaths per min (resonance breathing) to maximize respiratory and baroreflex effects on heart period oscillations. This intervention has wide-ranging clinical benefits and is gaining empirical support as an adjunct therapy for biobehavioral disorders, including asthma and depression. Yet, little is known about the system-level cardiovascular changes that occur during resonance breathing or the extent to which individuals differ in cardiovascular benefit. This study used a computational physiology approach to dynamically model the human cardiovascular system at rest and during resonance breathing. Noninvasive measurements of heart period, beat-to-beat systolic and diastolic blood pressure, and respiration period were obtained from 24 healthy young men and women. A model with respiration as input was parameterized to better understand how the cardiovascular processes that control variability in heart period and blood pressure change from rest to resonance breathing. The cost function used in model calibration corresponded to the difference between the experimental data and model outputs. A good match was observed between the data and model outputs (heart period, blood pressure, and corresponding power spectral densities). Significant improvements in several modeled cardiovascular functions (e.g., blood flow to internal organs, sensitivity of the sympathetic component of the baroreflex, ventricular elastance) were observed during resonance breathing. Individual differences in the magnitude and nature of these dynamic responses suggest that computational physiology may be clinically useful for tailoring heart rate variability biofeedback interventions for the needs of individual patients.

PMID: 25063789 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Roche scores upbeat data for a personalized asthma drug with blockbuster hopes – FierceBiotech


Drug Discovery & Development

Roche scores upbeat data for a personalized asthma drug with blockbuster hopes
FierceBiotech
Roche's ($RHHBY) lebrikizumab significantly reduced the rate of asthma attacks in patients with a severe form of the disease, according to mid-stage trial results, lighting the way for a Phase III study on the novel, personalized treatment. The drug
Biologic May Tame Severe AsthmaMedPage Today
Roche drug cuts asthma attacks, improves lung function -studyReuters
Lebrikizumab Phase 2b Data Show Reduction of Asthma Attack RatesDrug Discovery & Development
PharmaTimes
all 12 news articles »

View full post on asthma – Google News